News & Updates
Filter by Specialty:
Pembrolizumab shows durable efficacy in sorafenib-treated advanced HCC
14 Sep 2022
byChristina Lau
Pembrolizumab has demonstrated durable efficacy and a manageable adverse event (AE) profile in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib in a 5-year follow-up of the KEYNOTE-224 study.
Pembrolizumab shows durable efficacy in sorafenib-treated advanced HCC
14 Sep 2022Ivermectin not superior to placebo in mild COVID-19
13 Sep 2022
byStephen Padilla
Early treatment with single- or double-dose ivermectin is no better than placebo in avoiding progression to hospitalization and in improving symptoms in mild COVID-19, results of a study have shown.